CHIN-HSIAO TSENG2020-06-012020-06-0120130090-8258https://www.scopus.com/inward/record.uri?eid=2-s2.0-84885303854&doi=10.1016%2fj.ygyno.2013.07.087&partnerID=40&md5=48ef79c0af0f05ace8d77447b6212404https://scholars.lib.ntu.edu.tw/handle/123456789/496115Background. The association between pioglitazone and ovarian cancer has not been studied. Methods. The reimbursement databases of all Taiwanese patients with a diagnosis of diabetes and under oral anti-diabetic agents or insulin from 1996 to 2009 were retrieved from the National Health Insurance. An entry date was set at 1 January 2006 and a total of 546,632 female patients with type 2 diabetes were followed up for ovarian cancer incidence until the end of 2009. Incidences for ever-users, never-users and subgroups of pioglitazone exposure [using cutoffs of the Kaiser Permanente Northern California study and tertile cutoffs derived from the databases] were calculated and the hazard ratios were estimated by Cox regression in unadjusted, age-adjusted and fully adjusted models. Results. There were 30,783 ever-users and 515,849 never-users,with respective numbers of incident ovarian cancer of 49 (0.16%) and 946 (0.18%), and respective incidence of 43.08 and 51.47 per 100,000 person-years. The overall hazard ratios (95% confidence intervals) in unadjusted, age-adjusted and fully adjusted models were 0.822 (0.616-1.095), 0.823 (0.617-1.097) and 0.968 (0.718-1.305), respectively. In the dose-response analyses, none of the categories showed a significant hazard ratio, and all P-trendswere N0.05 without statistical significance. Conclusions. This study does not support a positive or negative association between pioglitazone use and ovarian cancer in female patients with type 2 diabetes. ? 2013 Elsevier Inc. All rights reserved.[SDGs]SDG3insulin; oral antidiabetic agent; pioglitazone; adult; aged; article; cancer incidence; cancer risk; controlled study; disease association; drug use; female; follow up; human; major clinical study; non insulin dependent diabetes mellitus; ovary cancer; priority journal; reimbursement; Taiwan; treatment durationjournal article10.1016/j.ygyno.2013.07.0872-s2.0-84885303854